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GENDER DIFFERENCES IN TREATMENT OUTCOMES AMONG 
FIBROMYALGIA PATIENTS 
ASHLEY A. HAAS 
Abstract 
Fibromyalgia is a chronic pain disorder that is characterized by widespread pain and 
additional somatic, cognitive, and mood symptoms.  Although there is no cure for 
fibromyalgia and it greatly impacts the lives of affected individuals, the research on 
gender differences in fibromyalgia symptomatology has largely been inconsistent.  No 
study, to date, has explored sustained outcomes in women versus men in the context of an 
interdisciplinary pain rehabilitation program (IPRP).  This retrospective study of 163 
(F=135, M=28) Cleveland Clinic Chronic Pain Rehabilitation Program participants 
investigated: 1) immediate and six month outcomes of fibromyalgia patients participating 
in an IPRP treatment and 2) whether there is a differential response to IPRP treatment 
across gender at discharge and six months following treatment.  IPRP treatment produced 
both clinically and statistically significant improvements for both men and women in 
pain, mood, and function. Women maintained these improvements at six months 
following treatment.  Men sustained statistically significant improvements but notable 
clinical improvements were only sustained for anxiety, stress, and pain.  No gender 
differences were present for men and women at admission or discharge.  At six months 
the only differences were that men reported more impairment related to functioning 
(F=7.37, p=.007), specifically in the areas of socialization (F=9.09, p=.003), occupation 
(F=9.51, p=.002), recreation (F=11.11, p=.001), and sexual activity (11.75, p=.001).  
 
 
v 
 
Further research is necessary to substantiate men’s greater impairment of functioning 
following IPRP treatment and explore variables associated with such.  
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CHAPTER I 
LITERATURE REVIEW 
 
1.1 Review of Relevant Literature 
 Although fibromyalgia is an incurable disorder that greatly impacts the lives of 
affected individuals, research regarding gender differences in symptomatology and long 
term outcomes after multidisciplinary treatment programs largely has been 
underinvestigated.  Fibromyalgia is a chronic pain disorder that is characterized by 
widespread pain throughout the body.  Individuals with the disorder often experience a 
combination of additional somatic symptoms, including fatigue, tenderness to touch or 
pressure, sleep problems, migraine or tension headaches, gastrointestinal difficulties such 
as irritable bowel syndrome, pelvic pain, an irritable or overactive bladder, and 
temporomandibular joint disorder (TMJ) (Crofford, 2013).  Some individuals may also 
experience: depression, anxiety, and memory problems or difficulty thinking clearly 
(Crofford, 2013).   
 The diagnosis of fibromyalgia was previously based primarily on tender point 
counts, in the absence of other explainable causes for widespread pain.  The 1990 
American College of Rheumatology criteria for the classification of fibromyalgia 
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required the presence of at least 11 of 18 possible tender points at a sensitivity rating of 
mild or greater (see Table 1).  Tender points include bilateral regions of the occiput, low 
cervical, trapezius, supraspinatus, second rib, lateral epicondyle, gluteal, greater 
trochanter, and knee (Wolfe et al., 1990) (see Figure 1).  Tender points are assessed by 
the examiner palpating with either the thumb, first two fingers, or first three fingers at a 
pressure of approximately 4 kilograms (Wolfe et al., 1990).  The tender points are 
considered to be mild if the patient complains of pain but does not grimace (defined as a 
“facial expression”), flinch (a “slight body movement”), or withdraw (move the area 
away from the examiner) (Wolfe et al., 1990).  Moderate tender points are determined by 
the presence of either flinching or grimacing at the experience of pain, and severe ratings 
are given to patients who flinch or withdraw in an exaggerated manner.  The last rating, 
unbearable, is reserved for patients who are unable to stand being touched and react with 
pain, even in the absence of palpation.  Furthermore, individuals are required to have had 
pain for three or more months and no other disorder could better account for the pain 
(Wolfe et al., 1990). 
 In 2010 the American College of Rheumatology released alternate guidelines for 
diagnosis in order to encompass the evolving conceptualization of fibromyalgia with the 
addition of somatic and cognitive symptoms and removal of tender point count as the 
defining characteristic of the disorder (Wolfe et al., 2010) (see Table 2),.  The 2010 
guidelines focus on two components: The Widespread Pain Index (WPI) and Symptom 
Severity (SS).  The WPI is an assessment of pain for the past week in 19 areas throughout 
the body.  The SS is a physician rated scale which specifies that symptoms must be 
present for at least three months at a similar level of pain or impairment (Wolfe et al., 
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2010).  Symptoms of fatigue, waking unrefreshed, and cognition are each rated on 
severity for the past week on a scale of 0 to 3.  Scores of 0 denote no symptoms, 1 means 
slight or mild problems, 2 indicates moderate, considerable, and/or often present 
problems, and 3 refers to severe symptoms (Wolfe et al., 2010).  Somatic symptoms are 
also rated on a scale of 0 to 3, indicating the number of symptoms the individual is 
experiencing: 0 indicates no symptoms, 1 is few symptoms, 2 indicates a moderate 
amount of symptoms, and 3 stands for many symptoms (Wolfe et al., 2010).  Scores from 
the fatigue, waking unrefreshed, cognition, and somatic symptom scales are summed to a 
final score that ranges from 0 to 12 (Wolfe et al., 2010).  The WPI and SS are used 
together for diagnosis, and the SS can be used independently to determine the severity of 
patients’ symptoms.  As with the 1990 criteria, there can be no other disorders that would 
better account for an individual’s pain and symptoms (Wolfe et al., 2010).   
 Fibromyalgia occurs in approximately two to four percent of the population 
(Crofford, 2013).  The 2008 estimate for adults with the disorder within the United States 
was five million (Lawrence et al., 2008).  Historically, prevalence rates of fibromyalgia 
among women and men varied considerably, with rates for women ranging from 3.4% to 
4.9% and men ranging from 0.2% to 1.6% (Mas et al., 2008; White et al., 1999; Wolfe, 
Ross, Anderson, Russell, & Hebert, 1995).   A recent study found that fibromyalgia was 
underdiagnosed in men at a 20-fold rate when comparing community based diagnoses 
with survey criteria (Vincent et al., 2013).  The inconsistency in prevalence rates may be 
attributed to recent changes in diagnostic criteria or problems inherent with previous 
criteria (Wolfe et al., 2013).       
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 Although clinical populations remain predominately female, recent prevalence 
rates for women and men are similar, 2.4% and 1.8% respectively (Wolfe, Brähler, Hinz, 
& Häuser, 2013).  The recent shift to similar prevalence rates between men and women 
can be attributed to the use of the 2010 criteria for the diagnosis of fibromyalgia.  
Accordingly, the 1990 criteria’s emphasis on tender point counts resulted in men being 
underdiagnosed with fibromyalgia, since women have been shown to have a greater 
number of tender points than men and have a significantly lower pain threshold than men 
(Castro-Sánchez et al., 2012; Häuser et al., 2011; LeResche, 2011; Vincent et al., 2013; 
Yunus, Inanici, Aldag, & Mangold, 2000).   
 Fibromyalgia greatly impacts the lives of affected individuals and carries stark 
societal costs.  The mean annual direct and indirect costs related to the disorder within the 
United States have been estimated at $10,219 to $42,456 per individual (Chandran et al., 
2012).  Furthermore, costs increased based on the severity of the disorder, along with 
corresponding medication use, emergency room visits, office visits to a physician, 
reduction of scheduled work time, days missed from work, and unemployment (Chandran 
et al., 2012).   
 The cause of fibromyalgia is uncertain.  The current consensus is that its etiology 
is multifactorial.  Psychological risk factors include childhood physical, sexual, and 
emotional abuse and living in a household as a child or adolescent with an individual who 
was depressed (Olivieri, Solitar, & Dubois, 2012).  Other factors associated with the 
disorder include: genetic, immunological, and hormonal susceptibilities, and autonomic 
nervous system and/or central nervous system dysfunction, such as central sensitization 
(Bellato et al., 2012; Meeus & Nijs, 2007).   
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 There is no cure for fibromyalgia.  Treatments that seek to alleviate symptoms of 
the disorder vary considerably from pharmacologic to non-pharmacologic treatments 
(Bellato et al., 2012).  Pharmacologic treatments that are moderately effective for the 
treatment of fibromyalgia include: tramadol (Ultram), duloxetine (Cymbalta), 
milnacipran (Savella), amitriptyline (Elavil), cyclobenzaprine (Flexiril), fluoxetine 
(Prozac), and pregabalin (Lyrica) (Häuser, Thieme, & Turk, 2010).   Moderately effective 
non-pharmacologic treatments are patient education, aerobic exercise, strength training, 
biofeedback, and psychological interventions, such as cognitive behavioral therapy 
(Ablin et al., 2013; Häuser, Thieme, & Turk, 2010).  However, pharmacologic and non-
pharmacologic approaches are minimally effective as stand-alone treatments for the long 
term management of fibromyalgia symptoms; therefore, multidisciplinary or 
interdisciplinary approaches that incorporate both pharmacologic and non-pharmacologic 
aspects of treatment are necessary to effectively treat the disorder (Carville et al., 2008; 
Crofford, 2013; Häuser et al., 2010; Marcus, 2009).    
 A multidisciplinary treatment approach incorporates health care providers from 
numerous disciplines who are working toward the common goal of improving clients’ 
symptoms and quality of life (Townsend, Bruce, Hooten, & Rome, 2006).  Compared to 
standard medical care, a multidisciplinary rehabilitation approach repeatedly has been 
shown to be more effective at improving  symptoms, health status, pain intensity, degree 
of disability, and mood for individuals with fibromyalgia, though research has primarily 
been obtained for the efficacy of treatment on women (Anderson & Winkler, 2006; 
Carbonell-Baeza et al., 2011; Lemstra & Olszynski, 2005).   
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 Interdisciplinary pain rehabilitation programs (IPRPs) are a type of   
multidisciplinary treatment approach in which a team of professionals across various 
disciplines, such as neurologists, psychiatrists, psychologists, nurses, social workers, 
physical therapists, occupational therapists and vocational rehabilitation counselors, work 
together in a coordinated, team-like environment to provide medical, physical, 
occupational, and psychological therapies to patients with chronic pain.  The aim of such 
programs is to teach self-management for a chronic, incurable condition and to increase 
functioning for such patients.  Empirical reviews support the efficacy of IPRPs for 
patients with fibromyalgia through significant improvements in pain, mood, function, and 
health care utilization by effectively reducing pain, distress, physical impairment, 
anxiety, and depression (Turk, Okifji, Sinclair, & Starz, 1998).  While findings for 
improvements in pain, mood, and functioning have been shown at 3 to 12 month follow-
up (Angst, Brioschi, Main, Lehmann, & Aeschlimann, 2006; Martin et al., 2012), 
research has not yet substantiated long-term benefits of IPRPs for fibromyalgia.  Further 
research is therefore necessary to provide additional support for the long-term benefits 
and sustainability of benefits of an IPRP for individuals with fibromyalgia.   
 
1.2 Gender Differences among Fibromyalgia Patients  
 A substantial amount of research exists that supports gender differences in the 
experience of pain (Hirsh, Waxenberg, Atchison, Gremillion, & Robinson, 2006; Keogh 
& Herdenfeldt, 2002; Paller, Campbell, Edwards, & Dobs, 2009).  As fibromyalgia is a 
chronic pain disorder that is characterized by persistent, widespread pain, one would 
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expect that gender differences exist among affected individuals.  This area of research, 
however, has largely been underinvestigated.  
 A literature review was conducted to compare studies that explored gender 
differences among individuals with fibromyalgia.  This review focused on studies that 
had either been written in or translated into English.  A total of 10 studies met these 
criteria.  Gender differences in fibromyalgia predominately have focused on three areas 
of symptom differentiation: pain, mood, and function.  Gender differences for pain 
previously focused on pain severity, pain intensity, current pain, and pain in the past two 
weeks.  Mood differences for men and women have looked at stress, depression, and 
anxiety scores.  Functioning differences for men and women have involved physical, 
emotional, and social functioning levels, life interference due to pain, and disability 
ratings.  Despite a common belief that gender differences in fibromyalgia have been well 
established, studies reported extremely inconsistent findings for males and females 
related to pain, mood, and function.    
 
1.2.1 Gender Differences and Pain 
 Four studies found no differences in fibromyalgia pain as a function of gender 
(Aparicio et al., 2012; Gormson, Rosenberg, Bach, & Jensen, 2010; White, Speechley, 
Harth, & Østbye, 1999; Yunus et al., 2000).  In contrast, two studies did find gender 
differences in fibromyalgia pain, and the results were mixed.  Buskila, Neumann, 
Alhoashle, and Abu-Shakra (2000) found that men reported significantly higher current 
pain.  However, a recent study by Castro-Sanchez et al. (2012) found that women 
experienced greater pain intensity than men.   
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1.2.2 Gender Differences and Mood 
 Studies exploring mood in individuals with fibromyalgia similarly reported varied 
results.  Five studies found no differences in mood across gender (Aparicio et al., 2012; 
Gormsen et al., 2010; Häuser et al., 2011; White at al., 1999; Yunus, Celiker, & Aldag, 
2004).  Three studies, conversely, found differences in gender for mood.  Buskila et al. 
(2000) found that men had higher rates of depression than women.  The study by Castro-
Sánchez et al. (2012), however, contradicts these findings, as women had significantly 
higher depression scores than men.  Consistent with the findings of Castro-Sánchez et al., 
a 2007 national epidemiologic study of depression and chronic pain conditions in Canada 
found that women with fibromyalgia had almost double the prevalence rates of 
depression than men (23.7% and 13.9% respectively) (Munce & Stewart).   
 
1.2.3 Gender Differences and Function 
 Findings of gender differences in functioning for fibromyalgia patients were also 
mixed.  Three studies found no differences between men and women in terms of 
functioning (Gormsen et al., 2010; White et al., 1999; Yunus et al., 2000).  In contrast, 
three studies found that men had greater impairment in functioning than women 
(Aparicio et al., 2012; Buskila et al., 2000; Castro-Sánchez et al., 2012).  Among these 
three, inconsistencies for specific areas of impairment across pain-related functioning 
were present.  Aparicio et al. (2012) found that men reported significantly more 
impairment related to the vitality subscale of the Short Form Health Survey-36 (SF-36), 
while Buskila et al. (2000) found that males had significantly more impairment on the 
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SF-36 subscale measuring role limitations related to emotional functioning.  Castro- 
Sánchez et al. (2012) concluded that men reported experienced significantly more 
impairments on the physical function scale of the Fibromyalgia Impact Questionnaire.   
 
1.2.4 Gender Differences in Pain Rehabilitation Programs  
 Only one study has been conducted to explore gender differences in a pain 
rehabilitation program setting.  Hooten, Townsend, and Decker (2007) compared gender 
differences among fibromyalgia patients at program admission and discharge, unlike the 
cross sectional snapshots of the previous studies, and found no differences in pain or 
mood.  In terms of functioning, they found that women had greater overall impairment in 
life interference due to pain upon admission and at discharge, specifically in the areas 
related to perceived health status and limitation in roles due to emotional interference.  
Additionally, women experienced significantly greater impairment in social functioning.  
Men, however, experienced less improvement in interference with life; therefore, at 
discharge they had more overall impairment due to pain (Hooten et al., 2007).  This 
suggests that although women report greater impairments initially, men experience 
greater difficulties related to impairment and do not experience as many treatment gains 
related to functioning.  Hooten et al. (2007) concluded that the investigation of post-
treatment outcomes as necessary to ascertain whether gender differences among 
fibromyalgia patients are persistent upon discharge.   
 
1.2.5 Inconsistencies among Previous Studies 
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 Differences in populations, samples, and p-value significance levels of analyses 
within the previous studies may account for the above noted inconsistencies.  Cultural, 
linguistic, and demographic differences may have affected the results as they were 
conducted in six countries.  Five studies were conducted in North America (Hooten et al., 
2007; Munce & Stewart, 2007; White et al., 1999; Yunus et al., 2000; Yunus et al., 
2004), and five were conducted in European and Middle Eastern countries, which 
consisted of two in Spain, and one each in Israel, Germany, and Denmark (Aparicio et al., 
2012; Castro-Sánchez et al., 2012; Gormsen et al., 2010; Häuser et al., 2011; Buskila et 
al., 2000; Gormsen et al., 2010, respectively).  The studies also varied in terms of sample 
size, which ranged from 48 to 131,535 (Castro-Sánchez et al., 2012; Munce and Stewart, 
2007) and involved both clinical (Aparicio et al., 2012; Buskila et al., 2000; Castro-
Sánchez et al., 2012; Gormsen et al., 2009; Häuser et al., 2011; Hooten et al., 2007; 
Yunus et al., 2000; Yunus et al. 2004) and population based participants (Häuser et al., 
2011; Munce and Stewart, 2007; White et al., 1999).  
 Additionally, p-value significance levels among the data analyses varied from 
p<.05 (Castro-Sánchez et al., 2012; Gormson et al., 2010; Häuser et al., 2011) to p<.01 
(Yunus et al., 2010; Yunus et al., 2004).  Variation of p-value significance may explain 
why some studies reported significant findings, while others reported findings that were 
not statistically significant.  For example, Yunus (2004) used a p-value of p<.01 and 
determined that anxiety at p<0.02 and stress at p<0.04 were not significant. Castro-
Sánchez (2012), however, used a p-value of p<.05 allowing mean pain at p=.015, 
disability at p=.010, and depression at p=.013 to be statistically significant.  Likewise, 
using p<.05 allowed Buskila et al. (2000) to determine that current pain was significant at 
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p=.029, Aparicio et al. (2013) to conclude physical impairment was significant at p=.017, 
and Hooten et al. (2007) to identify significant results related to functioning (p=.017), 
health perception (p=.023), role-limitations physical (p=.021), and social functioning 
(p=.033). 
  
1.3 Research Questions 
 The literature suggests that patients with fibromyalgia do improve (at least 
moderately) with interdisciplinary treatment approaches, but it is not known how such 
outcomes are maintained in the long term, and more specifically across genders.  The 
present study seeks to explore the sustainability of IPRP treatment with specific attention 
to gender differences.   
 Since no previous study has explored gender differences in the long term 
outcomes (6 months) of fibromyalgia patients, it is unknown what outcomes such 
exploration may produce.  Furthermore, only Hooten et al. have examined gender 
differences in an IPRP treatment approach.  Because these findings have yet to be 
replicated, any conclusions about treatment effects can only be preliminary, and 
additional research is needed.  Findings for clinical and population based cross sectional 
snapshot studies have produced inconsistent findings and, therefore, do not allow for any 
generalizations of gender differences among individuals with fibromyalgia.  
 Due to these reasons it is difficult to hypothesize what findings such an 
exploration of gender differences among long term outcomes of IPRP treatment may 
produce; therefore, the following research questions are posed.  First, is IPRP 
participation beneficial for both women and men?  In other words, do both men’s and 
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women’s symptoms improve from IPRP participation?  Secondly, if men and women do 
improve from IPRP participation, are these improvements sustainable in the long term, 
follow-up period?  Lastly, do differences across genders for IPRP fibromyalgia patients 
exist at either admission, discharge, or six month follow-up for pain, mood, and 
functioning?  This study seeks to address these research questions, discuss the 
implications of findings, and explore the generalizability of findings to other 
interdisciplinary pain rehabilitation programs.    
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CHAPTER II 
METHODS  
 
2.1 Procedure 
A retrospective study was conducted with patients of Cleveland Clinic’s Chronic Pain 
Rehabilitation Program (CPRP).  The study was approved by the Institutional Review 
Boards (IRBs) of Cleveland Clinic and Cleveland State University.  The Cleveland 
Clinic’s CPRP is an interdisciplinary pain rehabilitation day treatment program that lasts 
an average of three-and-a-half weeks.  Participants attend the program five days per week 
(Monday to Friday) from 7:30 a.m. to 5:00 p.m.  Program components include: physical 
and occupational therapies, coping skills training, individual and group psychotherapies 
(cognitive behavioral therapy, psychodynamic group therapy, family therapy and 
education, and biofeedback training), medication management including monitored 
weaning of patients from habituating medications, and substance use education, if 
indicated.   
 Patients within the program complete a packet of assessments measuring pain, 
mood, pain-related functioning, and other relevant psychological variables such as pain 
catastrophizing, and emotional expressiveness at admission, discharge, and six month 
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follow-up.  Patients provide demographic information including age, marital status, and 
the number of years they have been experiencing pain.  Patients undergo medical 
evaluation (including a physical exam) upon admission and assessments by physical and 
occupational therapists at admission and discharge.  Patient admission, discharge, and six 
month follow-up scores for pain, mood, and pain-related functioning assessments were 
utilized in this study.  The Numerical Rating Scale-11 was used as the measure of patient 
pain.  Mood was assessed by the Depression, Anxiety, and Stress Scales-42 or the 
Depression, Anxiety, and Stress Scales-21.  Impairments in functioning were 
approximated using patient scores from the Pain Disability Index.  These instruments are 
described more fully below.  
 
2.2 Participants 
Patient data were obtained from fibromyalgia patients from January 1, 2006 to October 2, 
2013 who were participating in the Chronic Pain Rehabilitation Program.  Patients were 
diagnosed with fibromyalgia prior to or on admission to the CPRP based on a review of 
medical history and a physical examination conducted by a trained rheumatologist or pain 
physician using either the American College of Rheumatology’s 1990 or 2010 criteria for 
fibromyalgia.  Participants were excluded from the program if they were actively 
psychotic, using illicit drugs, dependent upon alcohol, had an untreated medical 
condition, or if they were thought to be at imminent risk for suicide.  Follow-up data were 
obtained through mailed correspondence at six months following patient discharge.  All 
correspondence was coded to allow patients to return follow-up material anonymously. 
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 Of 615 fibromyalgia patients who completed the program during this time, 163 
patients (females=135, males=28) completed the Depression, Anxiety, and Stress Scales, 
Pain Disability Index, and Numerical Rating Scale assessments for admission, discharge, 
and six month follow-up and were included in analyses.  
   
2.3 Measurements 
2.3.1 Pain Disability Index  
The Pain Disability Index (PDI) is an 11-point Likert scale that ranges from scores of 0 
(no disability) to 10 (worst disability) (see Appendix A).  The PDI is a brief measure that 
addresses seven categories of interference in functioning: family and home 
responsibilities, recreation, social activity, occupation, sexual behavior, self-care, and 
life-support activities (Tait, Chibnall, & Krause, 1990).  Total scores for the PDI are the 
sum of scores from all categories and range from 0 to 70.  The PDI has demonstrated 
modest reliability for use as an assessment measure for chronic pain with a test-retest 
reliability of r = 0.44 and internal consistency of α = 0.86.  It has good validity with 
concurrent validity of p<0.05 with the University of Alabama-Birmingham pain behavior 
scale patient ratings of grimacing and posturing and nurse ratings of patient complaints, 
body language, and non-verbal indications of pain and construct validity of Multiple R = 
0.74 (Tait, Chibnall, & Krause, 1990).   
 
2.3.2 Depression, Anxiety, and Stress Scale-42 
The Depression, Anxiety, and Stress Scales-42 (DASS-42) are a 42-item self-report 
questionnaire designed to assess depression, anxiety, and stress (see Appendix B).  The 
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DASS-42 has 14 items on each of the subscales (depression, anxiety, and stress).  The 
DASS-42 was given to all patients from 2006 to 2011.  Patients rated each item of the 
scales as either: 0 “did not apply to me at all,” 1 “applied to me to some degree, or some 
of the time,” 2 “applied to me to a considerable degree, or a good part of time,” or 3 
“applied to me very much, or most of the time” (Psychology Foundation of Australia, 
2013).  Scores for each scale range from 0 to 42.  
 The DASS-42 has shown to be reliable with internal consistencies of α = .933 for 
the depression scale, α = .897 for the anxiety scale, stress scale of α = .933, and total 
score of α = .966 and shows temporal stability, obtained using paired t-tests to determine 
whether any significant differences were present between  patients’ scores in a two week 
period since analysis of test-retest reliability would be unable to account for patient 
change between administration due to the possibility of patients scores naturally changing 
between the two week test-retest period (Brown et al., 1996; Crawford & Henry, 2007).  
It has demonstrated convergent validity for the depression scale with the Personal 
Disturbance Scale (sAD) depression scale at r = .78 and Hospital Anxiety and Depression 
Scale (HADS) depression scale at r = .66 and for the anxiety scale with sAD anxiety 
scale at r = .72 and HADS anxiety scale at r = .62 (Crawford & Henry, 2007).   
 The DASS-42 is valid for use in chronic pain with good convergent validity for 
the DASS depression scale with the Beck Depression Inventory at r = .81 and Profile of 
Mood States (POMS) Depression scale at r = .84 and the DASS anxiety scale with the 
POMS Tension scale at r = .71 (Scheman, Janotta, & Covington, 2007).  Notably, the 
DASS-42 depression scale has demonstrated a possible ceiling effect when a large 
proportion of depressed patients received the maximum score (Page, Hooke, & Morrison, 
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2007; Scheman, Janotta, Bena, & Covington, 2007).  Patients’ depression, anxiety, and 
stress scales scores were included in analyses.  
 
2.3.3 Depression, Anxiety, and Stress Scales-21 
The Depression, Anxiety, and Stress Scales-21 (DASS-21) is a 21 item short form 
version of the original DASS-42 and is scored by doubling the sum of scores for each of 
the three scales: depression, anxiety, and stress (Psychology Foundation of Australia, 
2013) (see Appendix C).  The 21 items were selected based on good factor loadings, their 
ability to assess each subscale, and the obtainment of similar scale scores to the 42 items 
by doubling the scores of the each subscale for DASS-21 (Psychology Foundation of 
Australia, 2013).  The reliable (internal consistency of α = .91 depression scale, α = .80 
anxiety scale, and α = .84 stress scale) and valid (convergent validity with Mental 
Component Summary from r = -.58 to -.69) short form was implemented in Cleveland 
Clinic’s CPRP in 2012 (Sinclair et al., 2012).  The DASS-21 has been shown to produce 
depression, anxiety, and stress score means that are nearly identical to those of the 
DASS-42 for clinical (Anthony et al., 1998) and chronic pain patients (Olthoff & 
Fishman, 2010).   Patients from 2012 to 2013 completed this questionnaire.    
  
2.3.4 Numerical Rating Scale-11 
The Numerical Rating Scale-11 is an 11-point Likert scale used to measure patient pain, 
with scores that range from 0, no pain, to 10, worst pain possible (Hawker et al., 2011) 
(see Appendix D).  The scale has demonstrated good test-retest reliability at r = .95-.96 
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and strong construct validity with the Visual Analog Scale in patients with rheumatoid 
arthritis and other chronic pain conditions at r = .86 (Hawker et al., 2011).  
 
2.4 Data Analyses 
2.4.1 Repeated Measures Analysis of Variance  
Repeated measures analyses of variance (ANOVAS) were conducted with PDI, DASS 
depression, DASS anxiety, DASS stress, and Numerical Rating Scale scores for 
admission, discharge, and six months.  At the indication of a gender difference for a 
variable, repeated measures analyses of variance for admission to discharge and 
discharge to six months were conducted to determine at what time point the gender 
difference occurred.  Six month univariate ANOVAS were also used for PDI Scale scores 
to determine the presence of gender differences for specific scales upon findings of 
significant differences for patient’s overall scores at six month follow-up.  Levene’s Test 
was used to test homogeneity of variances.  For all analyses, p < 0.01 was established as 
the cut-off for significance.   
 
2.4.2 Analysis of Covariance 
Analyses of covariance (ANCOVAS) were run using participant admission scores as the 
covariant to determine whether statistical significance could be attributed to variance 
associated with differences in the men’s and women’s scores and not with variance 
among admission scores.  Controlling for the variance within admission scores ensured 
that statistical significance was not better attributed to one group coming into the 
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program with a higher mean score, and therefore, their scores remaining higher than the 
other group’s at the two other points. 
  
2.3.5 Clinically Significant Change 
Participants’ mean scores were given clinical classifications for anxiety, depression, 
stress, disability due to pain, and pain at admission, discharge, and follow-up.  Clinical 
classifications for depression are as follows: 0-7=normal, 8-9=mild, 10-14=moderate, 15-
19=severe, and ≥20 extremely severe (Lovibond & Lovibond, 1995).  Clinical 
classifications for anxiety are 0-9 normal, 10-13 mild, 14-20 moderate, 21-27 severe, and 
≥28 extremely severe (Lovibond & Lovibond, 1995).  For stress, 0 to 14 is normal, 15 to 
18 is mild, moderate is 19 to 25, 26-33 is severe, and extremely severe are scores greater 
than 34 (Lovibond & Lovibond, 1995).  Pain classifications are 0 (no pain), 1-4 (mild 
pain), 5-6 (moderate pain), and 7-10 (severe pain) (Turner, 2004).  The common practice 
of the Neurological Center for Pain of Cleveland Clinic is to rate disability due to pain 
none to mild for scores between 0 and 10, mild to moderate for scores in the 10 to 30 
range, moderate to severe for scores between 30 and 50, and 50 to 70 denotes severe 
disability.  Clinically significant change for each measures is considered a categorical 
shift for participants’ mean scores among extremely severe, severe, moderate, mild, and 
normal classifications between two time points (admission to discharge or discharge to 
six month).   
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CHAPTER III 
RESULTS 
 
3.1 Participant Demographic Information 
The mean age of participants was 46.2 years.  The mean age of men was 46.4 years, and 
the mean age of women was 45.3 years.  The majority of participants, 64.4%, were 
married.  Nineteen percent were single, 1.2% separated, 11% divorced, 3.1% cohabitate, 
1.2% were widowed.  The majority of men were married (64.3%).  Of the remainder, 
21.4% were single, 10.7% divorced, and 3.6% cohabitated.  No men were separated or 
widowers.  The majority of women were also married (64.4%), with 18.5% single, 1.5% 
separated, 11.1% divorced, 3.0% cohabitated, and 1.5% were widows.  Participants’ 
mean duration of pain was 16.1 years.  Men’s mean duration of pain was 14.6 years and 
women’s was 16.4 years.  Chi-square analyses were used to determine that no significant 
differences for age, marital status, pain duration, pain, mood, and function were identified 
between men and women (see Table 3). 
 
3.2 Missing Data for Pain, Mood, and Function 
Of 615 total CPRP participants from 2006 to 2013, 509 completed the program (82.8%).  
The 106 participants who did not complete the program were not included in analyses.  
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Comparisons were conducted by chi-square analyses to determine whether effect 
differences were present among program completers versus those who did not complete 
the program (see Table 4).  No differences were present for participants’ mood, function, 
gender, marital status, or age.  Analyses revealed that participants who did not complete 
the program had a shorter duration of pain (M=14.27 years, SD=11.80) and higher 
admission pain (M=7.33, SD=1.94) than participants who did complete the program 
(M=14.85 years, SD=11.41; M=6.85, SD=1.83).    
 185 of 509 CPRP program completers returned follow-up questionnaires at six 
months post treatment (36.3%).  Chi-square analyses were conducted to determine 
whether differences in effects were present for participants who returned follow-up 
questionnaires versus those who did not (see Table 5).  Comparisons determined that 
participants who did not return the follow-up data entered the program with higher 
anxiety (M=15.49, SD=11.31) and greater impairments in functioning (M=43.91, 
SD=13.83) but shorter duration of pain (M=13.71 years, SD=10.79) than those who did 
return follow up (M=13.79, SD=9.50; M=42.28, SD=12.87; and M=15.22 years, 
SD=11.85 respectfully).  
 Twenty two of the remaining 185 participants were excluded from analyses 
(11.89% of 185 follow up) because 50% or more of their data for one or more 
assessments and/or time points was missing.  Participants’ failure to complete at least 
50% of assessments was considered invalid for determining program efficacy.   
 To determine the most appropriate method for handling missing data, repeated 
measures ANOVAS were conducted (see Table 6).  Means of the 163 remaining 
participants (labeled true means) were compared to means of missing data that was 
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handled either by replacing them with series means (labeled replaced) or by further 
excluding them from analyses (labeled deleted).  Analyses determined that replacing 
missing data with series mean was the most appropriate for analyses, since means for 
both men and women were most closely matched or identical to those which included 
missing data.  Replacing missing data did not alter the outcomes of statistical tests for 
significance.  
 Participants with less than 50% incomplete or missing data for time points and 
assessments were still included in analyses, but series means were used to account for 
missing values.  Table 7 shows variables for which means were replaced, the total 
number of participants whose missing data was replaced, and what percentage their 
missing data accounted for of the total number of participants included in analyses.  
 
3.3 Missing Data for Pain Disability Index Scales 
Comparison of participants mean scores were again conducted using repeated measures 
ANOVAS to determine the most appropriate way of handling missing data for the seven 
PDI scales (see Table 8).  Analyses determined that replacing missing data with series 
means remained the most appropriate method for handling missing data, since the means 
of the participants before handling missing data was either most closely matched or 
identical to the data using replaced series means for both men and women.  Table 9 
displays the number of participants who had missing data replaced for five of the seven 
scales and the percentage they represented of the 163 participants included in analyses 
(see Table 9).   
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3.4 Comparison of DASS-42 and DASS-21 
Analyses of variance were conducted to ensure that participant’s mean depression, 
anxiety, and stress scale scores did not differ between those that completed the DASS-42 
and DASS-21.  Although the majority of participants (67%) completed the DASS-42, no 
statistically significant differences were found between DASS-42 and DASS-21 
admission, discharge, or six month-follow up mean scores among the depression, anxiety, 
and stress scales scores.  
 
3.5 Clinical and Statistical Benefits of IPRP for Fibromyalgia: Admission to Discharge 
 Patient scores were compared using repeated measures ANOVAS to determine 
the efficacy of the program (see Tables 10 and 11).  Admission to discharge scores for 
pain, mood, and function were compared to determine whether men and women benefited 
from CPRP participation.  Analyses revealed that both men and women experienced 
statistically significant improvements from CPRP participation among all measures at 
p<.001 (see Tables 12 and 13).   
 Patients also experienced notable clinical improvements from CPRP participation 
(see Table 14).  Notable clinical improvements are shifts among clinical ranges from 
admission to program discharge.  Women and men entered the program with moderate 
levels of depression and anxiety, which returned to normal upon program completion.   
Participants entered the program with severe levels of stress and experienced 
normalization of stress at program completion.  Severe levels of pain were reported for 
women and men, which were reduced to mild at discharge.  Participants entered the 
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program with moderate to severe levels of disability but experienced improvement as 
they shifted to the mild to moderate range at discharge.   
 
3.6 Maintenance of Statistical and Clinical IPRP Improvements for Fibromyalgia: 
Discharge to Six Months 
Six months following treatment, men and women continued to experience statistical 
improvements from admission levels among all measures (see Tables 15 and 17).  
Although a statistically significant difference was noted in participants’ discharge and six 
month scores (see Table 16), improvements from admission levels continued at the six 
month follow-up.  The continuance of notable clinical improvements were determined by 
whether men and women retained the normalization (i.e., their clinical levels remained 
within the normal ranges) of mood, pain, and function or instead if there was a 
categorical shift in clinical classification from discharge to six months.  Clinically, 
women retained improvements among all measures.  Men, however, only retained 
clinical improvements for anxiety, stress, and pain, since their depression and function 
levels returned to admission ranges (see Table 14). 
 
3.7 Gender Differences Among Fibromyalgia Patients at Admission and Discharge 
The presence of gender differences were explored at three time points of the CPRP: 
admission, discharge, and six month follow up.  Gender differences were not present at 
admission and discharge for any measure (see Table 19).  Analyses indicated that a time 
by gender interaction was not present, in other words, patient CPRP improvements from 
admission to discharge are not affected by gender (Table 12).  These findings suggest that 
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an interdisciplinary treatment program does not initially produce differential results for 
pain, mood, and function for men and women.  
 
3.8 Gender Differences in Function at Six Month Follow-Up 
Statistically significant gender differences emerged at six month follow-up.  A significant 
time by gender interaction for function was present for patients from discharge to six 
month follow-up, meaning that from discharge to six months CPRP benefits in function 
are affected by gender (see Table 16).  At six months following treatment, men reported 
significantly higher rates of total disability than women (F=7.37, p=.007).  Further 
analysis of specific areas of impairment for men revealed gender differences for four of 
the seven domains of the Pain Disability Index at six month follow-up.  Men reported 
significantly higher rates of impairment related to the recreation (F=11.11, p=.001), 
social activity (F=9.09, p=.003), occupation (F=9.51, p=.002) and sexual behavior (11.75, 
p=.001) domains of the Pain Disability Index (see Tables 19 and 20).  These findings 
suggest that although men and women do not initially respond differentially to treatment 
(see Table 12), that is, gender does not affect whether they both improve from admission 
to discharge, time by gender effects are noted from discharge to six month follow-up 
since men experience difficulty maintaining IPRP improvements, in terms of pain related 
functioning (see Table 16). 
  
3.9 Homogeneity of Variance 
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Levene’s test of homogeneity of variance was conducted to test for equality of variance.  
It determined that the assumption of equality of variance had not been violated for any 
measure (see Table 21).  
 
3.10 Controlling for Admission Scores 
Analyses of Covariance (ANCOVAS) were employed to control for possible differences 
in scores at admission.  Similar to previous findings, men and women demonstrated 
improvements among all measures even when controlling for admission scores (see Table 
22).  The improvements following participation in the IPRP remained statistically 
significant among all measures at p<.001 despite controlling for admission scores.   
Controlling for admission scores among women and men determined that admission 
scores do not affect the presence of gender differences in function from discharge to six 
months (see Table 22).   
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CHAPTER IV 
DISCUSSION 
 
 The results of this study demonstrate that both men and women experienced 
normalization of anxiety, stress, and pain at CPRP completion and sustained these 
treatment gains six months following treatment.  Furthermore, findings suggest that men 
and women with fibromyalgia experience stress, anxiety, and pain equally at admission, 
discharge, and six months following treatment since time by gender interactions were not 
present.  Men and women experienced normalization of functioning and depression at 
discharge but men do not sustain clinical improvements at six month follow-up, despite 
initial CPRP gains.  A comparison of statistically significant differences of time by 
gender interactions among participants’ scores for total disability and among the seven 
domains of the PDI revealed that men experience statistically greater impairment in 
functioning, specifically in the areas of the recreation, social activity, occupation, and 
sexual behavior domains of the Pain Disability Index.   
 Possible factors accounting for gender differences among IPRP participants with 
fibromyalgia may include differences in the experience of chronic pain and fibromyalgia 
symptomatology.  Research on gender differences in chronic pain has demonstrated that 
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disability is more closely associated with pain in men than women (Hirsch et al., 2006).  
Additionally, women with fibromyalgia have been shown to have a lower pain threshold 
when assessing tender points, thus raising concern of inaccurate diagnosis of 
fibromyalgia in men (Marcus, 2009).  Differences in survey response styles and treatment 
seeking behaviors between women and men may also influence results.  Furthermore, it 
should be considered whether it is these variables that are ultimately responsible for 
findings of greater impairment in men or if men with fibromyalgia do actually experience 
greater impairments in functioning.  
Findings from previous studies have supported the present study’s findings of no 
gender differences for mood and pain (Aparicio et al., 2012; Gormsen, 2010; Häuser et 
al., 2011; Hooten et al., 2007; White at al., 1999; Yunus, 2004; Yunus, 2000).  Likewise, 
the presence of gender differences in functioning in this study, specifically men reporting 
greater impairment than women, has been supported by previous studies (Aparicio et al., 
2012; Buskila et al., 2000; Castro-Sánchez et al., 2012).   
Several studies did not find gender differences in fibromyalgia (Gormsen et al., 
2010; White et al., 1999; Yunus et al., 2000).  The different results may relate to the way 
participants were selected for inclusion.  Previous studies used the American College of 
Rheumatology 1990 criteria for the diagnosis of fibromyalgia, while the present study 
included participants who were diagnosed using both the 1990 and 2010 criteria.  
This study has several limitations that should be considered.  First, multiple 
comparisons could have increased the risk of a Type I error, though a reduced p value of 
p<.01 and repeated measures ANOVAS were used to reduce this risk as much as 
possible.  Secondly, a discrepancy is present in the number of men versus women 
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included in analyses, although analyses revealed that differences were not present for 
demographic variables.  Another concern is the possibility of non-random selection, since 
patients who participated in the program had the financial, health care, and motivational 
means for doing so.  Due to this self-selection bias, results of CPRP participants may not 
be generalizable to all individuals within the community with fibromyalgia.  The sample 
of patients in this study were characterized by moderate levels of anxiety and depression, 
severe levels of stress and pain, and moderate to severe levels of impairment in function. 
Although the data reported here are consistent with some studies that involved 
nonclinical samples (e.g., no differences in pain or mood; White et al., 2000), 
fibromyalgia symptomology is highly variable and many individuals with fibromyalgia 
are high functioning without such severe levels of pain and stress.  Additionally, 
participants were diagnosed using either the 1990 and 2010 American College of 
Rheumatology’s criteria for the diagnosis of fibromyalgia, which may have resulted in a 
sample that is not fully homogeneous.  Furthermore, bias may have been introduced into 
the analyses by including only those participants who completed admission, discharge, 
and six month follow-up assessments.  Comparisons among CPRP completers versus 
noncompleters and participants returning six month follow-up versus those who did not 
was conducted to explore these risks.  Chi-square analyses found that participants who 
did not complete the program had a lower duration of pain and higher pain at admission, 
and participants who did not return follow-up data had higher admission anxiety and 
impairments in functioning and lower duration of pain.  In addition, a larger sample size 
would have provided more power to analyze the data but was not available due to the 
retrospective nature of the study.  Lastly, medication usage may influence many of the 
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outcome measures in the study.  Opioid usage has been associated with an increased risk 
of program noncompletion but this study did not account for use at admission (Dersh et 
al., 2008).  Importantly, research suggests that IPRP participants who undergo analgesic 
medication withdrawal receive significant pain, mood, and functioning improvements 
and sustain them six months following treatment (Hooten, Townsend, Sletten, Bruce, & 
Rome, 2007; Kidner, Mayer, & Gatchel, 2009; Rome et al., 2004; Townsend et al., 
2008).  Additionally, gender differences among pre and post IPRP treatment that 
incorporated opioid withdrawal have not been reported (Hooten et al., 2007).   
These findings may not be generalizable to all interdisciplinary pain approach 
programs since program components and psychological theoretical orientations vary 
among IPRPs.  Cleveland Clinic’s theoretical approach is more psychodynamic in nature 
than many other programs, though cognitive behavioral therapy components are included 
as a part of the treatment.  Other programs adhere more strictly to a cognitive and/or 
purely behavioral perspective.  Additionally, Cleveland Clinic’s CPRP includes the 
weaning of habituating medication, such as opioids, which is not included in all IPRPs.  
These differences should be accounted for when drawing conclusions from this study to 
other IPRPs.  Furthermore, including only participants who completed the program and 
returned follow-up data in analyses resulted in participant differences versus those who 
did not complete the program or did not return follow-up data.  These differences should 
be taken into account before determining the generalizability of these data to the general 
population of individuals with fibromyalgia.  
Additional research is needed to substantiate the findings reported in this study, 
since it is the first to include exploration across genders for sustained outcomes of 
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fibromyalgia patients.  Further analyses should be conducted to include longer term (e.g., 
12-18 months) outcomes to determine the extent to which improvement persists 
following IPRP treatment.   
The findings of this study are important, since they suggest that both men and 
women with fibromyalgia do improve from IPRP treatment and that men may struggle 
more so in the areas of depression and functioning after treatment.  Future research 
should explore interventions that may enhance or improve long-term outcomes in men 
with fibromyalgia who participate in IPRPs.  Tailoring program components to remediate 
men’s difficulty with sustaining IPRP improvements could enhance treatment benefits.  
In this regard, it would appear to be particularly beneficial to incorporate therapies 
specifically tailored to address men’s impairments in functioning in the realms of 
recreation, social activity, occupation, and sexual behavior.  These findings are important 
clinically, since they demonstrate that men’s concerns in these areas must be addressed 
during treatment in order for men to be able to sustain improvements regardless of initial 
treatment outcomes.   
Variables that may account for men’s differential response post treatment should 
also be explored, such as the psychological, physical, or cognitive factors that result in 
men’s increased impairment in functioning between discharge and six months follow-up. 
Additional follow-up treatment may be necessary which incorporates additional therapies 
that address men’s concerns regarding occupation, social activity, recreation, and sexual 
behavior domains of the Pain Disability Index to increase long term total level of 
functioning.  Participation in outpatient fibromyalgia groups specifically for men may be 
beneficial to address these concerns in an environment that allows for free exchange of 
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problems, concerns, and questions regarding these areas.  Additionally, men struggle to 
maintain treatment gains due to the stigmatizing nature of the view of fibromyalgia as a 
predominantly female oriented diagnosis.  They may also challenge to accept the 
diagnosis since fibromyalgia is a poorly understood medical disorder that for some 
individuals is still conceptualized to be a somatoform disorder.  Interventions that focus 
on acceptance and understanding of the disorder may lead to enhanced treatment 
sustainability.   
Importantly, future research should also investigate the impact of men’s inability 
to sustain treatment gains for men on their overall level of functioning with fibromyalgia.  
Long term outcomes may show men’s inability to sustain IPRP treatment gains 
profoundly affects them in all areas of their lives.  In addition to improving the lives of 
affected individuals, increased understanding of long term outcomes and appropriate 
interventions for improving treatment sustainability will improve the stark societal costs 
of fibromyalgia.   
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Table 1. The 1990 American College of Rheumatology Criteria for the Classification of 
Fibromyalgia  
  
1.    History of widespread pain 
 
Definition. Pain is considered widespread when all of the following are present: pain 
in the left side of the body, pain in the right side of the body, pain above the waist, 
and pain below the waist. In addition, axial skeletal pain (cervical spine or anterior 
chest or thoracic spine or low back) must be present. In this definition, shoulder 
and buttock pain is considered as pain for each involved side. “Low back” pain is 
considered segment pain. 
 
2.      Pain in 11 of 18 tender point sites on digital palpation.  
Definition. Pain, on digital palpation, must be present in at least 11 of the 
following 18 tender point sites: 
Occiput: bilateral, at the suboccipital muscle insertions. 
Low cervical: bilateral, at the anterior aspects of the intertransverse spaces at C5-
C7. 
Trapezius: bilateral, at the midpoint of the upper border. 
Supraspinatus: bilateral, at origins, above the scapula spine near the medial 
border. 
Second rib: bilateral, at the second costochondral junctions, just lateral to the 
junctions on upper surfaces. 
Lateral epicondyle: bilateral, 2 cm distal to the epicondyles. 
Gluteal: bilateral, in upper outer quadrants of buttocks in anterior fold of muscle. 
Greater trochanter: bilateral, posterior to the trochanteric prominence. 
Knee: bilateral, at the medial fat pad proximal to the joint line. 
 
Digital palpation should be performed with an approximate force of 4 kg. 
For a tender point to be considered “positive” the subject must state that the 
palpations was painful.  “Tender” is not to be considered “painful.” 
 
For classification purposes, patients will be said to have fibromyalgia if both criteria are 
satisfied. Widespread pain must have been present for at least 3 months. The presence of 
a second clinical disorder does not exclude the diagnosis of fibromyalgia.  
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Table 2. The American College of Rheumatology 2010 Preliminary Diagnostic Criteria 
for Fibromyalgia  
Criteria 
A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are 
met: 
1)  Widespread pain index (WPI) ≥7 and Symptom Severity (SS) score ≥5 or WPI 
between 3 and 6 and SS ≥ 9 
2)  Symptoms have been present at a similar level for at least 3 months 
3)  The patient does not have a disorder that would otherwise explain the pain 
 
Ascertainment 
1) WPI: note the number of areas in which the patient has had pain over the last week. 
In how many areas has the patient had pain? Score will be between 0 and 19: 
Shoulder girdle, left  Hip (buttock, trochanter), left Jaw, left Upper back 
Shoulder girdle, right  Hip (buttock, trochanter), right Jaw, right Lower back 
Upper arm, left  Upper leg, left Chest Neck 
Upper arm, right  Upper leg, right Abdomen 
Lower arm, left Lower leg, left 
Lower arm, right Lower leg, right 
 
2) SS Scale Score: 
Fatigue 
Waking unrefreshed  
Cognitive symptoms 
 
For each of the 3 symptoms above, indicate the level of severity over the last week 
using the following scale: 
0 = no problem 
1 = slight or mild problems, generally mild or intermittent 
2 = moderate, considerable problems, often present and/or at a moderate level 
3 = severe: pervasive, continuous, life-disturbing problems 
 
Considering somatic symptoms* in general, indicate whether the patient has: 
0 = no symptoms 
1= few symptoms 
2 = a moderate number of symptoms 
3 = a great deal of symptoms 
 
The SS scale score is the sum of the severity of the 3 symptoms (fatigue, waking 
unrefreshed, cognitive symptoms) plus the extent (severity) of somatic symptoms in 
general. The final score is between 0 and 12. 
 
*Somatic symptoms that might be considered: muscle pain, irritable bowel syndrome, 
fatigue/tiredness, thinking or remembering problem, muscle weakness, headache, 
pain/cramps in the abdomen, numbness/tingling, dizziness, insomnia, depression, 
constipation, pain in the upper abdomen, nausea, nervousness, chest pain, blurred vision, 
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fever, diarrhea, dry mouth, itching, wheezing, Raynaud’s phenomenon, hives/welts, 
ringing in ears, vomiting, heartburn, oral ulcers, loss of/change in taste, seizures, dry 
eyes, shortness of breath, loss of appetite, rash, sun sensitivity, hearing difficulties, easy 
bruising, hair loss, frequent urination, painful urination, and bladder spasms.  
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Table 3. Pearson Chi-Square Analysis for Women and Men 
 Value Df 
Asymp Sig. 
(2-sided) 
Age 48.246 51 .584 
Marital Status .964 5 .965 
Pain Duration 47.720 43 .287 
Admission Pain 12.681 12 .393 
Discharge Pain 7.074 14 .932 
Six Months Pain 7.003 15 .958 
Admission Depression 38.509 33 .234 
Discharge Depression 33.996 26 .135 
Six Months Depression 47.171 36 .101 
Admission Anxiety 31.570 36 .679 
Discharge Anxiety 18.896 22 .652 
Six Months Anxiety 25.236 26 .506 
Admission Stress 45.140 35 .117 
Discharge Stress 28.455 28 .441 
Six Months Stress 36.811 31 .218 
Admission Function 48.642 48 .447 
Discharge Function 41.170 40 .419 
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Table 4. Pearson Chi-Square Analysis for Program Completion 
 Value Df 
Asymp Sig. 
(2-sided) 
Age 60.851 66 .656 
Marital Status 4.212 5 .519 
Gender .117 1 .732 
Pain Duration 87.001 61 .016 
Admission Pain 28.091 15 .021 
Admission Depression 55.497 45 .136 
Admission Anxiety 50.081 45 .279 
Admission Stress 56.498 45 .117 
Admission Function 18.084 14 .203 
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Table 5. Pearson Chi-Square Analysis for Follow-Up 
 Value Df 
Asymp Sig. 
(2-sided) 
Age 83.468 64 .052 
Marital Status 6.949 6 .326 
Gender 1.236 3 .740 
Pain Duration 70.300 52 .046 
Admission Pain 24.681 19 .171 
Discharge Pain 26.000 17 .074 
Admission Depression 44.297 45 .502 
Discharge Depression 41.135 42 .509 
Admission Anxiety 65.416 43 .015 
Discharge Anxiety 29.938 36 .751 
Admission Stress 51.212 43 .212 
Discharge Stress 42.553 38 .281 
Admission Function 106.852 61 .000 
Discharge Function 50.736 51 .484 
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Table 6. Comparison of Means for Pain, Mood, and Function Admission, Discharge, 
and Six Month Follow-Up Scores 
  True Means 
Replaced 
W=135 M=28 
Deleted 
W=114 M=22 
  N Mean SD Mean SD Mean SD 
Depression 
Admission 
Women 
Men 
135 
28 
17.99 
20.54 
12.30 
12.35 
17.99 
20.54 
12.30 
12.35 
18.40 
22.09 
14.41 
12.03 
Anxiety 
Admission 
Women 
Men 
135 
28 
13.50 
12.54 
9.89 
8.27 
13.50 
12.54 
9.89 
8.27 
14.02 
12.64 
9.99 
8.27 
Stress 
Admission 
Women 
Men 
133 
27 
18.30 
19.44 
11.27 
9.79 
18.30 
19.44 
11.27 
9.79 
18.46 
20.45 
11.23 
9.85 
Pain 
Admission 
Women 
Men 
132 
28 
6.53 
7.07 
1.91 
1.70 
6.54 
7.07 
1.89 
1.70 
6.60 
7.18 
1.89 
1.62 
Function 
Admission 
Women 
Men 
135 
28 
43.03 
42.54 
10.97 
11.34 
43.03 
42.54 
43.03 
42.54 
43.29 
42.36 
10.44 
12.47 
Depression 
Discharge 
Women 
Men 
135 
28 
5.42 
7.54 
8.19 
9.19 
5.42 
7.54 
5.42 
7.54 
5.32 
8.95 
8.26 
9.80 
Anxiety 
Discharge 
Women 
Men 
135 
28 
5.89 
5.93 
6.70 
5.56 
5.89 
5.93 
5.89 
5.93 
5.85 
6.36 
6.21 
6.00 
Stress 
Discharge 
Women 
Men 
133 
27 
8.36 
8.24 
8.29 
6.43 
8.36 
8.24 
8.23 
6.31 
8.04 
9.39 
8.13 
6.36 
Pain 
Discharge 
Women 
Men 
134 
28 
3.10 
3.00 
2.28 
1.91 
3.10 
3.00 
2.27 
1.91 
2.96 
3.09 
2.29 
1.66 
Function 
Discharge 
Women 
Men 
134 
28 
15.93 
18.45 
11.09 
9.45 
15.93 
18.45 
11.05 
9.45 
15.44 
18.39 
11.06 
8.16 
Depression 
Six Months 
Women 
Men 
134 
28 
10.70 
15.64 
10.96 
13.02 
10.70 
15.64 
10.92 
13.02 
10.84 
17.32 
11.39 
13.29 
Anxiety Six 
Months 
Women 
Men 
134 
28 
6.61 
8.96 
7.50 
8.51 
6.52 
8.96 
7.46 
8.51 
6.76 
10.32 
7.43 
8.64 
Stress Six 
Months 
Women 
Men 
125 
24 
11.40 
16.08 
10.53 
10.00 
11.45 
15.52 
10.13 
9.34 
11.49 
17.68 
10.62 
10.36 
Pain Six 
Months 
Women 
Men 
132 
28 
4.36 
4.86 
2.26 
2.16 
4.37 
4.86 
2.24 
2.16 
4.18 
5.00 
2.28 
2.29 
Function 
Six Months 
Women 
Men 
135 
28 
22.71 
33.43 
15.02 
16.09 
22.71 
33.43 
15.02 
16.09 
22.01 
33.59 
15.60 
15.31 
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Table 7. Replaced Means for Pain, Mood, and Function  
 Valid Data Missing Data 
 N Percent N Percent 
Duration Pain 162 99.4% 1 0.6% 
Depression 6 Months 162 99.4% 1 0.6% 
Anxiety 6 Months 162 99.4% 1 0.6% 
Stress Admission 160 98.2% 3 1.8% 
Stress Discharge 160 98.2% 3 1.8% 
Stress 6 Months 149 91.4% 14 8.6% 
Pain Admission 160 98.2% 3 1.8% 
Pain 6 Months 160 98.2% 3 1.8% 
Function Discharge 162 99.4% 1 0.6% 
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Table 8. Comparison of Means for Seven Scales of Pain Disability Index at Six Month 
Follow-Up  
  True Means 
Replaced 
W=135 M=28 
Deleted 
W=114 M=22 
  N Mean SD Mean SD Mean SD 
Family/ 
Home 
Women 
Men 
135 
27 
3.74 
4.56 
2.36 
2.65 
3.74 
4.53 
2.36 
2.60 
3.56 
4.68 
2.44 
2.61 
Recreation 
Women 
Men 
135 
28 
3.99 
5.82 
2.68 
2.51 
3.99 
5.82 
2.68 
2.51 
3.79 
5.77 
2.72 
2,25 
Social 
Women 
Men 
135 
28 
3.37 
5.00 
2.53 
2.94 
3.37 
5.00 
2.53 
2.94 
3.22 
5.00 
2.61 
2.91 
Occupation 
Women 
Men 
132 
27 
4.44 
6.37 
2.98 
2.80 
4.45 
6.31 
2.94 
2.77 
4.29 
6.36 
3.11 
2.80 
Sexual  
Behavior 
Women 
Men 
129 
28 
3.66 
6.04 
3.37 
3.43 
3.67 
6.04 
3.30 
3.43 
3.58 
5.91 
3.41 
3.32 
Self-Care 
Women 
Men 
134 
28 
2.07 
3.07 
2.35 
2.37 
2.07 
3.07 
2.34 
2.73 
2.00 
3.04 
2.34 
2.84 
Life Support 
Activities 
Women 
Men 
134 
28 
1.81 
2.86 
2.44 
2.88 
1.81 
2.86 
2.43 
2.88 
1.76 
2.82 
2.40 
2.89 
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Table 9. Replaced Means for the Pain Disability Index Scales  
 Valid Data Missing Data 
 N Percent N Percent 
PDI-Family/Home 6 Months 162 99.4% 1 0.6% 
PDI-Occupation 6 Months 159 97.5% 4 2.5% 
PDI-Sexual 6 Months 157 96.3% 6 3.7% 
PDI-Self-Care 6 Months 162 99.4% 1 0.6% 
PDI-Life Support 6 Months 162 99.4% 1 0.6% 
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Table 10. Mean and Standard Deviations for Women and Men for All 
Measures  
  N Mean SD 
Depression Admission Women 135 17.99 12.30 
 Men 28 20.54 12.35 
Depression Discharge Women 135 5.42 8.19 
 Men 28 7.54 9.19 
Depression 6 Months Women 135 10.70 10.92 
 Men 28 15.64 13.02 
Anxiety Admission Women 135 13.50 9.89 
 Men 28 12.54 8.27 
Anxiety Discharge Women 135 5.89 6.70 
 Men 28 5.93 5.56 
Anxiety 6 Months Women 135 6.62 7.47 
 Men 28 8.96 8.51 
Stress Admission Women 135 18.31 11.18 
 Men 28 19.41 9.61 
Stress Discharge Women 135 8.36 8.23 
 Men 28 8.24 6.31 
Stress 6 Months Women 135 11.45 10.13 
 Men 28 15.52 9.34 
Pain Admission Women 135 6.54 1.89 
 Men 28 7.07 1.70 
Pain Discharge Women 135 3.10 2.27 
 Men 28 3.00 1.91 
Pain 6 Months Women 135 4.37 2.34 
 Men 28 4.86 4.86 
Function Admission Women 135 43.03 10.97 
 Men 28 42.54 11.34 
Function Discharge Women 135 15.93 11.05 
 Men 28 18.45 9.45 
Function 6 Months Women 135 22.71 15.02 
 Men 28 33.43 16.09 
PDI-Family/Home 6 Months Women 135 3.74 2.36 
 Men 28 4.53 2.60 
PDI-Recreation 6 Months Women 135 3.99 2.68 
 Men 28 5.82 2.51 
PDI-Social Activity 6 Months Women 135 3.37 2.53 
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 Men 28 5.00 2.94 
PDI-Occupation 6 Months Women 135 4.45 2.94 
 Men 28 6.31 2.77 
PDI-Sexual Activity 6 Months Women 135 3.67 3.30 
 Men 28 6.04 3.43 
PDI-Self-Care 6 Months Women 135 2.07 2.34 
 Men 28 3.01 2.73 
PDI-Life Support 6 Months Women 135 1.81 2.43 
 Men 28 2.86 2.88 
 
Note Means displayed are actual means not adjusted means for covariates  
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Table 11. Repeated Measures Analysis of Variance Quadratic Contrasts 
Results: Admission, Discharge, and Six Months 
 Type III SS df 
Mean 
Square 
F Sig. 
 Depression      
Time 1720.543 2 1720.543 24.468 .000 
Gender 711.717 1 711.7171 3.418 .066 
Time * Gender 66.545 1 66.545 .946 .332 
Error (Time) 11321.286 160 70.319   
 Anxiety      
Time 1268.681 2 1268.681 34.806 .000 
Gender 15.609 1 15.609 .124 .725 
Time * Gender 127.600 1 127.600 3.501 .063 
Error (Time) 5869.029 160 36.447   
 Stress      
Time 1338.578 2 1338.578 28.036 .000 
Gender 197.651 1 197.651 2.137 .292 
Time * Gender 102.032 1 102.032 2.137 .146 
Error (Time) 7686.952 160 47.745   
 Pain      
Time 222.944 2 222.944 79.314 .000 
Gender 6.578 1 6.578 .931 .336 
Time * Gender .022 1 .022 .008 .929 
Error (Time) 452.556 160 2.811   
 Function      
Time 10039.837 2 10039.837 84.094 .000 
Gender 1255.643 1 1255.643 5.011 .027 
Time * Gender 1457.444 1 1457.444 12.208 .001 
Error (Time) 19221.491 160 119.388   
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Table 12. Repeated Measures Analysis of Variance Linear Contrasts Results: 
Admission to Discharge 
 Type III SS df 
Mean  
Square 
F Sig. 
 Depression      
Time 7581.380 1 7581.380 97.989 .000 
Gender 251.429 1 251.429 1.745 .188 
Time * Gender 2.140 1 2.140 .028 .868 
Error (Time) 12456.541 161 77.370   
 Anxiety      
Time 2345.271 1 2345.271 59.364 .000 
Gender 9.992 1 9.992 .104 .747 
Time * Gender 11.774 1 11.774 .298 .586 
Error (Time) 6360.574 161 39.507   
 Stress      
Time 5168.640 1 5168.640 92.953 .000 
Gender 11.294 1 11.294 .089 .766 
Time * Gender 17.245 1 17.245 .310 .578 
Error (Time) 8952.346 161 55.605   
 Pain      
Time 652.792 1 652.792 196.815 .000 
Gender 2.153 1 2.153 .426 .515 
Time * Gender 4.743 1 4.743 1.430 .234 
Error (Time) 534.001 161 3.317   
 Function      
Time 30375.519 1    30375.519 294.862 .000 
Gender 47.495 1 47.495 .351 .554 
Time * Gender 104.656 1 104.656 1.016 .315 
Error (Time) 16585.575 161 103.016   
 55 
 
 
 
 
 
 
 
 
 
 Table 13. Statistically Significant Participant Improvement: Admission and Discharge  
 Scores for Pain, Mood, and Function for Women and Men with  Fibromyalgia  
 Admission Discharge 
 
Women 
(N=135) 
Men 
(N=28) 
Women 
   (N=135) 
Men 
(N=28) 
Measure Mean SD Mean   SD Mean SD Mean SD 
Depression  17.99 12.3 20.54   12.3 5.42 8.2 7.54 9.2 
Anxiety  13.50 9.9 12.54  8.3 5.89 6.7 5.93 5.6 
Stress  18.31 1.2 19.41   9.6 8.36 8.2 8.24 6.3 
Pain   6.54 1.9 7.07   1.7 3.10 2.3 3.00 1.9 
Function  42.54 11.0 43.03   11.3 15.93 11.1 18.45 9.5 
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Table 14. Participants’ Clinical Classifications for Anxiety, Depression, Stress, Pain, 
and Function at Admission, Discharge, and Six Months Using Assessment Scores 
 Admission Discharge Six Months 
 Women Men Women Men Women Men 
Anxiety 13.50 
Moderate 
12.54 
Moderate 
5.89 
Normal 
5.93 
Normal 
6.62 
Normal 
8.96 
Mild 
Depression 17.99 
Moderate 
20.54 
Moderate 
5.42 
Normal 
7.54 
Normal 
10.70 
Mild 
15.64 
Moderate 
Stress 18.31 
Severe 
19.41 
Severe 
8.36 
Normal 
8.24 
Normal 
11.45 
Normal 
15.52 
Mild 
Pain 6.54 
Severe 
7.07 
Severe 
3.10 
Mild 
3.00 
Mild 
4.40 
Moderate 
4.86 
Moderate 
Function 43.03 
Moderate
-Severe 
42.54 
Moderate
-Severe 
15.93 
Mild-
Moderate 
18.45 
Mild-
Moderate 
22.71 
Mild-
Moderate 
33.43 
Moderate
-Severe 
 
Key for clinical classifications: Anxiety: 0-7=normal, 8-9=mild, 10-14=moderate, 15-
19=severe, ≥20=severe. Depression: 0-9=normal, 10-13=mild, 14-20=moderate, 21-
27=severe, ≥28=extremely severe. Stress: 0-14 normal, 15-18 mild, 19-25 moderate, 26-
33 severe, and 37+ extremely severe. Pain: 0=no pain, 1-3=mild pain, 4-6=moderate pain, 
7-10= severe pain. Disability due to pain rating: 0-10=none-mild, 10-30= mild-moderate, 
30-50=moderate to severe, 50-70=severe. Notable clinical change is considered a 
categorical shift from severe/moderate/mild/normal. 
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Table 15. Repeated Measures Analysis of Variance Linear Contrasts Results: 
Admission to Six Months 
 Type III SS df 
Mean 
Square 
F Sig. 
 Depression      
Time 1720.543 1 1720.543 24.468 .000 
Gender 649.077 1 649.077 3.111 .080 
Time * Gender 66.545 1 66.545 .946 .332 
Error (Time) 11321.286 161 70.319   
 Anxiety      
Time 1268.681 1 1268.861 34.809 .000 
Gender 22.125 1 22.125 .192 .662 
Time * Gender 127.600 1 127.600 3.501 .063 
Error (Time) 5868.029 161 36.447   
 Stress      
Time 1338.578 1 1338.578 28.036 .000 
Gender 310.270 1 310.270 1.806 .181 
Time * Gender 102.032 1 102.032 2.137 .146 
Error (Time) 7686.952 161 47.745   
 Pain      
Time 222.944 1 222.944 79.314 .000 
Gender 12.226 1 12.226 2.184 .141 
Time * Gender .022 1 .022 .008 .929 
Error (Time) 452.556 161 2.81   
 Function      
Time 10039.837 1 10039.837 84.094 .000 
Gender 1213.686 1 1213.686 5.199 .024 
Time * Gender 1457.444 1 1457.444 12.208 .001 
Error (Time) 19221.491 161 119.388   
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Table 16. Repeated Measures Analysis of Variance Linear Contrasts Results: 
Discharge to Six Months 
 Type III SS df 
Mean 
Square 
F Sig. 
 Depression      
Time 2078.602 1   2078.602 32.752 .000 
Gender 576.674 1 576.674 4.299 .040 
Time * Gender 92.544 1 92.544 1.458 .229 
Error (Time) 10217.964 161 63.466   
 Anxiety      
Time 164.082 1 164.082 6.108 .000 
Gender 66.178 1 66.178 .891 .347 
Time * Gender 61.854 1 61.854 2.303 .131 
Error (Time) 4325.010 161 28.863   
 Stress      
Time 1246.561 1 1246.561 22.683 .000 
Gender 181.220 1 181.220 1.677 .197 
Time * Gender 203.170 1 203.170 3.697 .056 
Error (Time) 8847.869 161 54.956   
 Pain      
Time 112.752 1 112.752 34.636 .000 
Gender 1.739 1 1.739 .263 .609 
Time * Gender 4.118 1 4.118 1.265 .161 
Error (Time) 524.116 161 3.255   
 Function      
Time 5488.847 1 5488.847 51.812 .000 
Gender 2031.138 1 2031.138 8.399 .004 
Time * Gender 780.998 1 780.998 7.371 .007 
Error (Time) 17055.979 161 105.938   
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Table 17. Statistically Significant Sustainability of Improvements: Six Month 
Follow-Up Scores for Pain, Mood, and Function for Women and Men with 
Fibromyalgia 
 Admission 
Six Month Follow Up 
 
Women 
(N=135) 
Men 
(N=28) 
Women 
(N=135) 
Men 
(N=28) 
Measure Mean SD Mean SD Mean SD Mean SD 
Depression   17.99 12.3 20.54 12.3 10.70 11.0 15.64  13.0 
Anxiety   13.50  9.9 12.54   8.3   6.61   7.5  8.96   8.5 
Stress   18.31  1.2 19.41  9.6 11.45 10.1 15.52   9.3 
Pain     6.54  1.9  7.07  1.7   4.4   2.2  4.86   2.2 
Function   43.03  11.0 42.54 11.3 22.71 15.0 33.43 16.1 
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Table 18. Gender Differences at Admission and Discharge 
 Admission Discharge 
 
Women 
 (N=135) 
Men 
(N=28) 
Women 
   (N=135) 
Men 
(N=28) 
 Measure Mean SD Mean  SD Mean SD Mean SD 
 Depression   17.99 12.3 20.54    12.3   10.70 11.0 15.64    13.0 
 Anxiety   13.50 9.9 12.54   8.3     6.61  7.5   8.96  8.5 
 Stress   18.31 1.2 19.41   9.6   11.45 10.1 15.52     9.3 
 Pain     6.54 1.9  7.07   1.7    4.4  2.2   4.86     2.2 
 Function    43.03 11.0 42.54    11.3   22.71 15.0 33.43    16.1 
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Table 19. Results for Univariate Analysis of Variance for  Pain Disability 
Index Domains: Tests of Between Subject Effects at Six Months 
 Type III SS df 
Mean  
Square 
F Sig. 
 PDI Family/Home      
Intercept 1586.829 1 1586.829 274.846 .000 
Gender 14.494 1 14.494 2.510 .115 
Error 929.537 161 5.774   
 PDI Recreation      
Intercept 2230.192 1   2230.192 316.750 .000 
Gender 78.192 1 78.192 11.106 .001 
Error 1133.578 161 7.041   
 PDI Social Activity      
Intercept 1624.776 1   1624.776 239.774 .000 
Gender 61.586 1 61.586 9.088 .003 
Error 1090.981 161 6.776   
 PDI Occupation      
Intercept 2684.803 1   2684.803 316.066 .000 
Gender 80.785 1 80.785 9.510 .002 
Error 1367.605 161 8.494   
 PDI Sexual Behavior      
Intercept 2186.296 1   2186.296 198.654 .000 
Gender 129.358 1 129.358 11.754 .001 
Error 1771.897 161 11.006   
 PDI Self-Care      
Intercept 612.646 1  612.646 105.349 .000 
Gender 23.329 1 23.329 4.011 .047 
Error 936.283 161 5.815   
 PDI Life Support      
Intercept 506.167 1  506.167 80.226 .000 
Gender 25.197 1 25.197 3.994 .047 
Error 1015.797 161 6.309   
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Table 20. Gender Differences for Function at Six Month Follow-Up 
 
Women 
(N=135) 
Men 
(N=28) 
Between Subjects 
 Measure Mean SD Mean   SD F p 
 Depression  17.99 12.3 20.54     12.3  1.488  .229 
 Anxiety  13.50 9.9 12.54      8.3   2.303 .131 
 Stress  18.31 1.2 19.41    9.6   3.697   .056 
 Pain   6.54 1.9 7.07    1.7   1.265  .162 
 Function   43.03 11.0 42.54     11.3   7.372     .007* 
 PDI Family/Home     3.74   2.36   4.53       2.60   2.510   .115 
 PDI Recreation     3.99   2.68   5.82       2.51  11.106      .001* 
 PDI Social Activity     3.37   2.53   5.00       2.94   9.088      .003* 
 PDI Occupation     4.45   2.94   6.31       2.77   9.510      .002* 
 PDI Sexual Behavior     3.67   3.30   6.04       3.43   11.754      .001* 
 PDI Self-Care     2.07   2.34   3.07        2.73   4.011   .047 
 PDI Life Support     1.81   2.43   2.86        2.88   3.994   .047 
*p denotes a significant difference of p<.01 for men’s and women’s’ scores at six  
      month follow-up 
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Table 21. Levene’s Test of Homogeneity of Variance 
 F DF1 DF2 Significance 
Depression Admission .003 1 161 .956 
Depression Discharge .737 1 161 .392 
Depression 6 Months 3.175 1 161 .077 
Anxiety Admission 1.108 1 161 .294 
Anxiety Discharge 1.170 1 161 .281 
Anxiety 6 Months 3.095 1 161 .080 
Stress Admission 1.250 1 161 .265 
Stress Discharge 1.743 1 161 .189 
Stress 6 Months .279 1 161 .598 
Pain Admission .867 1 161 .353 
Pain Discharge 1.594 1 161 .209 
Pain 6 Months .055 1 161 .814 
Function Admission .000 1 161 .990 
Function Discharge .128 1 161 .721 
Function 6 Months .366 1 161 .546 
PDI-Family/Home 6 Months .149 1 161 .700 
PDI-Recreation 6 Months .502 1 161 .480 
PDI-Social Activity 6 Months 1.861 1 161 .174 
PDI-Occupation 6 Months .314 1 161 .576 
PDI-Sexual Activity 6 Months .000 1 161 .986 
PDI-Self-Care 6 Months 1.310 1 161 .254 
PDI-Life Support 6 Months 1.497 1 161 .223 
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Table 22. Gender Differences for Discharge to Six Months When Controlling for 
Admission Scores Using Linear Contrasts  
 Type III SS Df 
Mean 
Square 
F Sig. 
Depression      
Time 87.702 1 87.702 1.472 .227 
Gender 327.428 1 327.428 3.272 .072 
Depression 
Admission 
5586.776 1 5586.776 55.828 .000 
Time * Gender 56.973 1 56.973 .956 .330 
Error (Time) 9535.566 159 59.597   
Anxiety      
Time 2.366 1 2.366 .090 .765 
Gender 110.729 1 110.729 2.211 .139 
Anxiety 
Admission 
3948.275 1 3948.275 78.839 .000 
Time * Gender 68.112 1 68.112 2.584 .046 
Error (Time) 4218.046 159 26.363   
Stress      
Time 17.933 1 17.933 .342 .559 
Gender 107.820 1 107.820 1.573 .212 
Stress 
Admission 
6429.126 1 6429.126 93.769 .000 
Time * Gender 179.970 1 179.970 3.346 .066 
Error (Time) 8379.626 159 52.373   
Pain      
Time 1.508 1 1.508 .466 .496 
Gender .016 1 .016 .003 .959 
Pain 
Admission 
119.285 1 119.285 20.215 .000 
Time * Gender 3.040 1 3.040 .940 .334 
Error (Time) 517.761 159 3.236   
Function      
Time 58.008 1 58.008 .582 .447 
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Gender 2122.022 1 2122.022 9.594 .002 
Function 
Admission 
3543.355 1 3543.355 16.019 .000 
Time * Gender 812.387 1 812.387 8.148 .005 
Error (Time) 15952.752 159 99.705   
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Figure I. Tender point locations for the American College of Rheumatology 1990 criteria 
for the classification of fibromyalgia 
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APPENDIX A 
PAIN DISABILITY INDEX 
Pain Disability Index: The rating scales below are designed to measure the degree to 
which aspects of your life are disrupted by chronic pain. In other words, we would like to 
know how much pain is preventing you from doing what you would normally do or from 
doing it as well as you normally would. Respond to each category indicating the overall 
impact of pain in your life, not just when pain is at its worst.  
  
For each of the 7 categories of life activity listed, please circle the number on the scale 
that describes the level of disability you typically experience. A score of 0 means no 
disability at all, and a score of 10 signifies that all of the activities in which you would 
normally be involved have been totally disrupted or prevented by your pain.  
  
Family/Home Responsibilities: This category refers to activities of the home or family. It 
includes chores or duties performed around the house (e.g. yard work) and errands or 
favors for other family members (e.g. driving the children to school).  
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
  
Recreation: This disability includes hobbies, sports, and other similar leisure time 
activities. 
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
  
Social Activity: This category refers to activities, which involve participation with friends 
and acquaintances other than family members. It includes parties, theater, concerts, 
dining out, and other social functions.  
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
  
Occupation: This category refers to activities that are part of or directly related to one’s 
job. This includes non-paying jobs as well, such as that of a housewife or volunteer.  
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
  
Sexual Behavior: This category refers to the frequency and quality of one’s sex life.  
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
  
Self-Care: This category includes activities, which involve personal maintenance and 
independent daily living (e.g. taking a shower, driving, getting dressed, etc.)  
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
  
Life-Support Activities: This category refers to basic life supporting behaviors such as 
eating, sleeping and breathing.  
No Disability  0__  1__  2__  3__  4__  5__  6__  7 __  8__  9__  10__  Worst Disability  
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APPENDIX B 
DEPRESSION, ANXIETY, AND STRESS SCALES-42 
Please read each statement and circle a number 0, 1, 2, or 3 which indicates how much 
the statement applied to you over the past week 
 
The rating scale is as follows: 
0 Did not apply to me at all 
1 Applied to me to some degree, or some of the time. 
2 Applied to me a considerable degree, or a good part of the time. 
3 Applied to me very much, or most of the time. 
 
1.    I found myself getting upset by quite trivial things 0 1 2 3 
2.    I was aware of dryness of my mouth 0 1 2 3 
3.    I couldn't seem to experience any positive feeling  at all 0 1 2 3 
4.    I experienced breathing difficulty (e.g., excessively rapid 
breathing, breathlessness in the absence of physical exertion) 
0 1 2 3 
5.    I just couldn't seem to get going 0 1 2 3 
6.    I tended to over-react to situations 0 1 2 3 
7.    I had a feeling of shakiness (e.g., legs going to give way) 0 1 2 3 
8.    I found it difficult to relax 0 1 2 3 
9.    I found myself in situations that made me so anxious I was most 
relieved when they ended 
0 1 2 3 
10.  I felt that I had nothing to look forward to 0 1 2 3 
11.  I found myself getting upset rather easily 0 1 2 3 
12.  I felt that I was using a lot of nervous energy 0 1 2 3 
13.  I felt sad and depressed 0 1 2 3 
14.  I found myself getting impatient when I was delayed in any way 
(e.g., lifts, traffic lights, being kept waiting) 
0 1 2 3 
15.  I had a feeling of faintness 0 1 2 3 
16.  I felt that I had lost interest in just about everything 0 1 2 3 
17.  I felt I wasn't worth much as a person 0 1 2 3 
18.  I felt that I was rather touchy 0 1 2 3 
19.  I perspired noticeably (e.g., hands sweaty) in the absence of high 
temperatures or physical exertion 
0 1 2 3 
20.  I felt scared without any good reason 0 1 2 3 
21.  I felt that life wasn't worthwhile 0 1 2 3 
22.  I found it hard to wind down 0 1 2 3 
23.  I had difficulty in swallowing 0 1 2 3 
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24.  I couldn't seem to get any enjoyment out of the things I did 0 1 2 3 
25.  I was aware of the action of my heart in the absence of physical 
exertion (e.g., sense of heart rate increase, heart missing a beat) 
0 1 2 3 
26.  I felt down-hearted and blue 0 1 2 3 
27.  I found that I was very irritable 0 1 2 3 
28.  I felt I was close to panic 0 1 2 3 
29.  I found it hard to calm down after something upset me 0 1 2 3 
30.  I feared that I would be "thrown" by some trivial but unfamiliar 
task 
0 1 2 3 
31.  I was unable to become enthusiastic about anything 0 1 2 3 
32.  I found it difficult to tolerate interruptions to what I was doing 0 1 2 3 
33.  I was in a state of nervous tension 0 1 2 3 
34.  I felt I was pretty worthless 0 1 2 3 
34.  I was intolerant of anything that kept me from getting on with 
what I was doing 
0 1 2 3 
36.  I felt terrified 0 1 2 3 
37.  I could see nothing in the future to be hopeful about 0 1 2 3 
38.  I felt that life was meaningless 0 1 2 3 
39.  I found myself getting agitated 0 1 2 3 
40.  I was worried about situations in which I might panic and make a 
fool of myself 
0 1 2 3 
41.  I experienced trembling (e.g., in the hands) 0 1 2 3 
42.  I found it difficult to work up the initiative to do things 0 1 2 3 
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APPENDIX C 
DEPRESSION, ANXIETY, AND STRESS SCALES-21 
Please read each statement and circle a number 0, 1, 2, or 3 which indicates how much 
the statement applied to you over the past week. There are no right or wrong answers. Do 
not spend too much time on any statement.  
 
The rating scale is as follows: 
0 Did not apply to me at all 
1 Applied to me to some degree, or some of the time. 
2 Applied to me a considerable degree, or a good part of the time. 
3 Applied to me very much, or most of the time. 
 
1.    I found it hard to wind down 0 1 2 3   
2.    I had difficulty in swallowing 0 1 2 3   
3.    I couldn't seem to get any enjoyment out of the things I did 0 1 2 3   
4.    I was aware of the action of my heart in the absence of physical 
exertion (e.g., sense of heart rate increase, heart missing a beat) 
0 1 2 3   
5.    I felt down-hearted and blue 0 1 2 3  
6.    I found that I was very irritable 0 1 2 3   
7.    I felt I was close to panic 0 1 2 3   
8.    I found it hard to calm down after something upset me 0 1 2 3   
9.    I feared that I would be “thrown” by some trivial but unfamiliar 
task 
0 1 2 3   
10.  I was unable to become  enthusiastic about anything 0 1 2 3   
11.  I found it difficult to tolerate interruptions to what I was doing 0 1 2 3   
12.  I was in a state of nervous tension  0 1 2 3   
13.  I felt I was pretty worthless 0 1 2 3   
14.  I was intolerant of anything that kept me from getting on with 
what I was doing 
0 1 2 3   
15.  I felt terrified 0 1 2 3   
16.  I could see nothing in the future to be hopeful about 0 1 2 3   
17.  I felt that life was meaningless 0 1 2 3   
18.  I found myself getting agitated 0 1 2 3   
19.  I was worried about situations in which I might panic and make 
a fool of myself 
0 1 2 3   
20.  I experienced trembling (e.g., in the hands) 0 1 2 3   
21.  I found it difficult to work up the initiative to do things 0 1 2 3   
       I have thoughts of killing myself 0 1 2 3 
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APPENDIX D 
NUMERICAL RATING SCALE 
 
Please rate your usual level of pain on a scale of 0 to 10 
0 1 2 3 4 5 6 7 8 9 10 
0 – No Pain 
10 – The worst pain you can imagine 
 
